

REVIEW

Open Access



The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer

Heying Duan and Andrei Iagaru *

Abstract

In the era of precision medicine, oncological imaging techniques are advancing at a rapid pace, particularly molecular imaging with promising new targets for prostate cancer (PC) such as gastrin releasing peptide receptors (GRPR) along the established and indispensable prostate specific membrane antigen (PSMA). As PC is characterized by heterogeneous tumor biology ranging from indolent to aggressive disease, distinguishing clinically significant tumors from indolent disease is critical. Multiparametric MRI- and PET-targeted prostate biopsies mitigate the shortcomings and risks of standard systematic template biopsy by identifying more significant cancers.

Focal treatment for localized disease is a minimally invasive approach that targets the index tumor – the lesion of the highest grade – while sparing the surrounding healthy tissue. Real-time MRI-guidance and thermal control with MR-thermometry, improves treatment accuracy and results in lower rates of functional side effects. PET imaging could be a useful tool to assess response to treatment compared to invasive prostate biopsies.

In this comprehensive review, we focus on the image-guided detection and treatment of localized primary prostate cancer, its current status and future perspectives.

Keywords: Image-guided, mpMRI, ⁶⁸ Ga-RM2, ⁶⁸ Ga-PSMA, PET, Prostate Cancer

Introduction

Prostate cancer (PC) is the most frequent non-cutaneous cancer in the US with one in every eight men diagnosed with PC during their lifetime [1]. Worldwide, PC is the second most frequent malignancy with an estimated 1.4 million new cases and 375,000 deaths ranking as the fifth leading cause of cancer deaths among men in 2020 [2]. Due to the high volume and population affected, PC is considered a global health problem. Screening for serum prostate specific antigen (PSA) has dramatically increased the diagnosis of PC; however, many are low-grade, clinically non-significant cancers, leading

to overdiagnosis and overtreatment. This resulted in an increase of therapy-associated side effects such as erectile dysfunction and incontinence, and of the economic burden on the healthcare system. *To screen, or not to screen, that is the question* or better put, the dilemma. There is a clinical need for faster and more accurate ways to identify clinically significant PC in order to reduce the harms of screening while maintaining the benefits.

The underlying tumor biology of PC is heterogeneous and on a spectrum with reclassification over time, spanning from indolent disease, characterized by Gleason score 3+3, to clinically significant, aggressive cancer with Gleason score $\geq 3+4$. It is not only important to differentiate between non-significant and significant cancers, but also whether the disease is localized or metastasized and if so, to what extent. Accurate detection of suspected PC is crucial to direct subsequent patient

*Correspondence: aiagaru@stanford.edu

Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA, USA



management. While low-risk and some subsets of intermediate-risk, indolent disease is typically cared for with active surveillance [3, 4], aggressive cancers require therapy. The treatment options are multifaceted and include prostatectomy, radiation therapy, hormonal therapy, chemotherapy, or a combination of these [5–7]. While a whole-gland treatment approach shows good oncological results, it may also have life-altering side effects such as incontinence, impotence, and infection [8]. As the majority of PC are localized within the prostate gland [9], minimal invasive local treatment approaches have been gaining in interest and popularity as the adverse events reported are low while having good oncological outcome [10].

The role of imaging is indispensable and used not only to detect PC, but also to assess tumor volume and extraprostatic extension, and to guide targeted biopsy and focal treatment. Multiparametric magnetic resonance imaging (mpMRI) has become the gold standard in staging PC as it has high sensitivity; mpMRI-targeted biopsies find more clinically significant and less insignificant tumors compared to systematic transrectal ultrasound (TRUS)-guided biopsies [11]. It is increasingly used for treatment planning and guidance of focal therapy in localized PC. However, there are limitations to mpMRI as clinically significant PC may be missed [12–16].

Molecular imaging with positron emission tomography (PET) combined with computed tomography (CT) or MRI provides anatomical and biological information of the whole body. Especially PET/MRI with its high soft tissue contrast is well-suited for staging PC. The functional information is obtained from agents that target different receptors on the PC cell. The most widely used radiopharmaceutical targets the prostate specific membrane antigen (PSMA) which is overexpressed in 90% of PC [17]. Another promising target is the gastrin releasing peptide receptor (GRPR) which is highly overexpressed in several cancers including PC with favorable characteristics for initial staging of PC [18–21].

In this review article, we focus on the *status quo* of image-guided, targeted prostate biopsies and focal treatments for localized primary PC using mpMRI and PET with gallium-68 (⁶⁸Ga) radiolabeled PSMA- and GRPR-targeting radiopharmaceuticals and give an outlook into future directions for image-guided interventions.

Image-guided prostate biopsy

PC is most often multifocal, arising in 80%–85% of cases from the peripheral zone, 10%–15% from the transition zone, and 5%–10% from the central zone [9]. The index lesion is the highest-grade tumor which drives subsequent management and clinical outcomes [22, 23]. The

role of imaging at initial staging is to distinguish clinically significant from indolent disease and to guide targeted biopsy of the index tumor.

mpMRI-guided biopsy

Traditionally, patients with elevated PSA undergo TRUS-guided biopsy using a non-targeted, systematic 12-core approach to sample the whole prostate. This technique leads to overdiagnosis of insignificant disease while missing clinically significant cancers. Especially cancers located anteriorly are difficult to reach, and are not always part of the biopsy template [24]. Furthermore, TRUS-guided biopsies are associated with more serious complications requiring hospital admission [25, 26].

mpMRI consists of 3 phases: T2 weighted imaging (T2WI) for anatomical, diffusion weighted images (DWI) for biological, and dynamic contrast-enhanced (DCE) imaging for vascular information. The added conspicuity of suspected lesions seen in these specific phases, interpreted using the Prostate Imaging Reporting and Data System (PI-RADS) score [27, 28], together with lesion volume, has increased the sensitivity and specificity for clinically significant cancers to a pooled 89% and 73%, respectively [29].

Multiple clinical trials investigated whether mpMRI can accurately stratify clinically significant to non-significant PC, and compared mpMRI-guided to standard TRUS-guided biopsy. The PROMIS study showed that mpMRI had significantly better sensitivity and negative predictive value for significant disease, and when used as a triage test in biopsy naïve patients, avoided unnecessary biopsies in 27% [30]. The PRECISION trial randomized 500 biopsy naïve men for mpMRI-targeted or systematic biopsy and showed similar results with mpMRI increasing the detection rate of clinically significant PC from 26 to 38%, while reducing the detection of insignificant disease from 22 to 9% [31]. In a head-to-head comparison of mpMRI- and TRUS-guided biopsy, the 4 M trial found identical detection rates of significant disease, but mpMRI detected fewer insignificant cancers and reduced biopsies by nearly 50% [13]. A combined mpMRI- and TRUS-guided biopsy approach, however, showed the best detection rate of clinically significant PC as 7% were missed when mpMRI-guided biopsy was performed alone. The MRI FIRST trial reported a similar miss rate of 5% for significant disease [14] while the TRIO study showed 9% misclassification for mpMRI-targeted biopsy [32]. These miss rates beg the need for other imaging modalities.

In a meta-analysis, mpMRI-targeted and systematic biopsies were compared to histopathology after prostatectomy: a tumor upgrade was found in 23% for mpMRI-targeted versus 43% for systematic biopsy [33]. The

PRECISE trial confirmed previous findings that a third of patients (37%) had a negative mpMRI and thus avoided biopsy [34]. mpMRI-targeted biopsy is non-inferior to systematic TRUS-guided biopsy in detecting clinically significant PC, however, the difference was lower (5.2%) than in the PRECISION trial (12%) suggesting that a combined approach might improve detection rates of significant disease.

MRI allows for in-bore or in-gantry biopsy where the procedure is performed in the MRI machine under real-time image guidance with the possibility for immediate correction of a suboptimal needle trajectory. A large case series including 554 patients undergoing in-bore MRI-targeted biopsy showed an overall detection rate of 80% for PC, and 55% for clinically significant disease, even in small, ≤ 5 mm tumors [35]. In patients with prior negative biopsy, PC was found in 60%, of which 80% were significant disease whereas the majority was located anterior in the prostate where TRUS-guided biopsy has known limitations. Half of the active surveillance cohort were upgraded after in-bore biopsy. In a comparison of in-bore MRI-guided and MRI-TRUS fusion-targeted biopsies, in-gantry biopsy detected more clinically significant (61%) and fewer insignificant (11%) PC lesions than MRI-TRUS fusion (41% and 18%, respectively) [36]. These results were validated by recently published studies focused on PI-RADS 4 and 5 lesions [37, 38]. Despite the growing evidence that in-bore MRI-targeted biopsies can accurately detect more significant disease, its use has been limited by the higher costs as MR-compatible instruments, access to scanner, and scanning time are required as well as the learning curve for the interventionist.

As the demand for mpMRI increases, faster imaging techniques are needed. In the updated PI-RADS classification [39], DCE was rated less significant, hence biparametric MRI (bpMRI) without the DCE phase might be useful. Several studies compared mpMRI to bpMRI and to 'fast' bpMRI consisting of only 1 plane versus the regular 3 planes. Similar detection rates were seen whereas bpMRI was non-inferior to mpMRI [40–43]. However, and this applies to mpMRI as well, the PROMIS and PRECISION trials have shown a slight discrepancy in expertise expressed as moderate agreement between the site-readers and central expert-readers despite the use of a standardized, PI-RADSV2 scoring system. Therefore, omitting the DCE phase may increase uncertainty in less experienced radiologists. mpMRI and bpMRI are only as good as the used equipment and the radiologist interpreting the images.

Despite these studies showing the overall better performance of mpMRI-targeted prostate biopsies, it is optional to add mpMRI-targeted to TRUS-guided prostate biopsy in biopsy-naïve patients according to the

current guidelines of the National Comprehensive Cancer Network (NCCN). However, in patients with prior negative prostate biopsy, mpMRI-targeted biopsy is recommended for repeat biopsy [44].

Advancements in new applications will further optimize image-guided interventions. An innovative way to integrate prior imaging into real-time biopsy is augmented reality. Through 'smart glasses', prior mpMRI was matched with real-time TRUS images at standard template fusion biopsy [45]. This approach yielded in a higher PC detection rate of 46% than standard biopsy at 27%. These encouraging results warrant more studies involving the rapidly developing field of novel technology.

PET-guided biopsies

As mpMRI misses 5–10% of clinically significant PC, especially in the 'blind spots' (transition and central zones) [46], and underestimates the actual tumor volume by up to 3 times (Fig. 1) [47], other modalities are needed to delineate all aggressive lesions. PSMA is a transmembrane protein which is overexpressed in PC [48]; PSMA-targeting compounds have shown high sensitivity and specificity at staging, treatment response evaluation, and biochemical recurrence. Retrospective studies comparing ^{68}Ga -PSMA11 PET/CT [49, 50] or PET/MRI [51] and mpMRI to post-prostatectomy histopathology demonstrated that ^{68}Ga -PSMA PET was superior than mpMRI alone, especially in the detection of additional and smaller cancer lesions. However, smaller lesion with high uptake on PET might lead to overestimation tumor volume due to partial volume effect.

The first prospective study on the feasibility of ^{68}Ga -PSMA617 PET/CT-guided biopsy evaluated men with prior negative standard biopsy but persistent clinical suspicion for PC [52]. On a per patient level, PET/CT-US-guided biopsy detected significant PC in 39% versus 32% for TRUS-guided, whereas a combined approach again increased detection to 67% in patients with positive ^{68}Ga -PSMA617 PET while neither targeted nor systematic biopsy detected clinically significant PC when ^{68}Ga -PSMA617 PET was negative. A prospective, single-center study compared ^{68}Ga -PSMA11 PET/MRI-guided to standard template biopsy in biopsy naïve patients: while PET/MRI showed a 90% accuracy for significant PC with high sensitivity (96%) and specificity (81%), PET-guided biopsy showed a decreased accuracy rate of 71% [53]. The work-up revealed that some of the PET-targeted lesions were missed suggesting that additional perilesional biopsy cores could improve accuracy. This was also observed in the 4 M trial comparing TRUS- to mpMRI-guided biopsy and was related to sampling errors due to spatial heterogeneity of the tumor [13]. When correlated to final




Fig. 1. 48-year-old man presents with PSA 11.30 ng/mL and PSA density 0.31 ng/mL² for targeted prostate biopsy: mpMRI **A** shows a PI-RADS 4 lesion in the right lateral base whereas ⁶⁸Ga-PSMA11 axial PET **B**, axial fused PET/MRI **C**, and maximum intensity projection (MIP) **D** reveal a larger tumor volume. Subsequent PET-targeted biopsy resulted in a Gleason score 4 + 3 prostate cancer

post-prostatectomy pathology, ‘false positive’ lesions at biopsy were in fact in 89% PC and proved only in 11% to be benign. As for ‘false negative’ lesions at biopsy, 50% were PC on final histology, 33% did not undergo surgery, and 17% were PC without PSMA expression on immunohistochemistry. This reflects the reported overall rate of PSMA-negative lesions of 5–10% [54, 55]. Lastly, omitting biopsy in patients with negative ⁶⁸Ga-PSMA11 PET/MRI would have reduced biopsy rate by 33% with missing significant disease in only one patient (7%) who had a PI-RADS 5 lesion on mpMRI.

The results of the prospective multicenter PRIMARY trial evaluating the added value of a pelvic PSMA PET/CT to standard mpMRI showed that a combined approach of PET/CT- and mpMRI-guided biopsy improved sensitivity (97% versus 83%) and negative predictive value (91% versus 72%) for clinically significant PC as compared to mpMRI alone [56]. Nineteen percent of men were negative in both modalities and could have avoided biopsy indicating that a combination of PET and mpMRI act as a better triage tool to discriminate between clinically significant and indolent disease than either one alone.

⁶⁸Ga-PSMA11 PET/CT was used to guide prostate biopsy through the gluteal muscle and identified clinically significant PC in 80% versus 25% by standard TRUS-guided biopsy [57]. The detection rate was significantly higher in ⁶⁸Ga-PSMA11 positive than negative scans whereas by omitting biopsy in PET negative patients, 6% of clinically significant cancers would have been missed. Therefore, the authors hypothesize, PET negative patients might benefit from active surveillance rather than excessive biopsies. This transgluteal biopsy technique had no adverse events whereas in the

TRUS-guided group, hematuria, urine retention, and infection were observed.

Fluorine-18 (¹⁸F)-radiolabeled PSMA ligands benefit from the more favorable physical properties: the lower kinetic energy results in a higher spatial resolution, and the longer half-life (110 versus 68 min) allows for a better tumor to background ratio in delayed imaging when compared to ⁶⁸Ga. Both, ⁶⁸Ga-PSMA11 and ¹⁸F-DCFPyL have been approved by the US Food and Drug Administration in 2021. The DeTeCT trial evaluated the performance of ¹⁸F-DCFPyL PET/CT in identifying primary PC and employed a prostate-mapping model to predict the potential outcome of ¹⁸F-DCFPyL PET/CT-targeted biopsy [58]. The detection rate of clinically significant PC was forecasted to be 93% with identification of the index lesion in 87%. Consequently, a pilot study investigated the feasibility of ¹⁸F-DCFPyL PET/CT- or PET/MRI-US-guided prostate biopsy [59]: The detection rate of significant disease was slightly higher for PET/CT-US- at 88% versus 83% for PET/MRI-US-guided biopsies. A small subgroup underwent both ¹⁸F-DCFPyL PET/CT and PET/MRI whereas MRI was able to confirm PET positive lesions as suspicious, or as benign which was validated by subsequent biopsy.

Lack of specificity of PSMA leads to false positives, while lack of expression of PSMA leads to false negatives [60–66], while up to 10% of PC do not express PSMA [55]. Consequently, other targets were developed. GRPR is highly overexpressed in several cancers including PC, especially in earlier stages, making it an attractive target for initial staging [18–21]. In a large pilot study including 112 men with suspected PC, ⁶⁸Ga-PSMA617-, the GRPR-targeting ⁶⁸Ga-RM26 PET/CT-, and mpMRI-targeted prostate biopsy were compared to standard

template biopsy [67]. The dual-tracer approach of ^{68}Ga -PSMA617- and ^{68}Ga -RM26-targeted biopsy showed the highest detection rate of 77% without missing any significant cancers. Single ^{68}Ga -PSMA617- and ^{68}Ga -RM26-guided detection rates were at 70% and 56%, respectively, whereas mpMRI-guided and standard biopsy were comparably low at 36% and 35%, respectively. Our group compared in a pilot study ^{68}Ga -PSMA11- and ^{68}Ga -RM2-PET-targeted biopsy in a selected cohort with negative or equivocal mpMRI and/or negative biopsy, but persistent clinical suspicion for PC (Fig. 2) [68]. The preliminary results showed that ^{68}Ga -RM2 was able to detect all clinically significant and non-significant PC with a high sensitivity of 83% whereas ^{68}Ga -PSMA11 showed a lower sensitivity of 63% and missed significant disease in 29%. The low PSMA detection rate is comparable to reported rates for this specific clinical scenario and might reflect a change in tumor biology [52]. PSMA and GRPR expression have been reported as complementary [69, 70], and as GRPR is particularly overexpressed in earlier stages of PC [18], GRPR-targeting

radiopharmaceuticals may be more suitable in this specific clinical scenario.

PET-guided biopsies can also be performed in-bore: A recently published study including 78 patients showed that the use of a robotic arm to assist with ^{68}Ga -PSMA11 PET/CT-targeted transgluteal prostatic biopsy is not only safe but detected PC in 96% of patients whereas 44% were clinically significant [71].

mpMRI- and PET-targeted prostate biopsy have shown to have a higher detection rate for clinically significant PC than standard template biopsy. Further prospective studies are needed to answer the central question whether targeted biopsy can retire systematic biopsy. As PET with its added costs may not be easily added to the diagnostic algorithm of PC, it may become relevant when mpMRI is negative or equivocal, or MRI-guided biopsy is negative.

PET-guided prostate biopsy is currently not mentioned in any guidelines. However, the updated NCCN guidelines now recommend PSMA-PET as first-line imaging tool as it is 'equally effective, if not more effective than




Fig. 2. 62-year-old man with PSA 7.0 ng/mL and PSA density 0.24 ng/mL². MRI shows a PI-RADS 4 lesion in the right lateral base with color coded needle tracks from biopsy; green-benign, yellow-Gleason score 3 + 3, red-Gleason score 3 + 4 or higher **A**, and target tumor volume **B**. ^{68}Ga -PSMA11 **C** and ^{68}Ga -RM2 **D** axial PET, axial fused PET/MRI, and MIP show congruent focal uptake in the right prostate lesion. The lesion was treated with HIFU; resolution on both ^{68}Ga -PSMA11 and ^{68}Ga -RM2 PET/MRI was seen 6 months after treatment

conventional imaging' at both initial staging and biochemical recurrence [72].

Image-guided focal treatments

As up to 95% of newly diagnosed PC are localized within the prostate gland and are nonmetastatic [9], image-guided, targeted, local treatments might be an advantageous option. Although PC presents in most cases multifocally, the ablation of the index tumor, which is the main driver for morbidity, can lead to tumor control. Minimally invasive, local treatments for PC employ ablation with heat such as high intensity focused ultrasound (HIFU) and focal laser ablation (FLA), or freezing with needle cryoprobes amongst a vast array of different other focal treatments. These procedures aim at the index lesion while sparing the surrounding healthy tissue including the urethra and bladder, the neurovascular bundles, and the rectum. Local therapy approaches preserve continence in 98% and sexual function in 90% of patients compared to whole-gland treatment, leading to only minimal impact on quality of life. [10, 73]. Cancer control over 8 years were similar in a propensity score matched cohort of 335 patients undergoing radical prostatectomy and 501 patients receiving focal therapy [74]. However, long-term data from randomized controlled trials are sparse.

mpMRI-guided focal treatment

Therapy planning includes identification of the index lesion, assessment of tumor volume and extent of disease. As tumor volume is known to be underestimated by mpMRI, especially tumors with high Gleason scores and small lesions [75], a 20% larger treatment zone than the actual index lesion on mpMRI combined with a 9 mm margin around the lesion has been proposed to ensure treatment of the entire tumor [76, 77].

HIFU

HIFU is a noninvasive local treatment that employs high-frequency sonographic waves to deliver focal, high energy to the tumor, reaching a temperature of approximately 80 °C causing thermal, mechanical, and tissue effects leading to coagulation necrosis [78]. The probe is commonly placed transrectally and heat is applied for seconds followed by a cooling period to protect rectal mucosa. After HIFU, the lesion may appear cystic with increased T2 signal intensity and hypovascular on contrast-enhanced MRI [79].

Most studies with long-term follow-up data use mpMRI-TRUS fusion HIFU. These studies have shown promising results with low in-field recurrence, i.e., within the treatment zone, of 13% and low urinary incontinence rate of 2% at 5-year follow-up [80]. Erectile dysfunction

was seen in 10% and increased insignificantly after repeat HIFU to 21% [73]. Re-treatment with HIFU was necessary for the majority of patients after initial HIFU within a follow-up period of 8 years [81].

In-bore HIFU uses real-time MR imaging to track and guide the HIFU probe and leverages MR thermometry for real-time heat mapping to ensure a precise ablation of the tumor [82]. A first feasibility study showed in 14 patients with low-volume and low-grade PC that this technique is feasible and safe with only transient insignificant deterioration in urinary and sexual function, which resolved within 3 months after HIFU. At 6-month biopsy, 7% of patients showed persistent significant in-field disease, and 17% at 24-month biopsy. As this was a pilot study on safety and feasibility, patients with insignificant disease were also included. Another pilot study evaluated 8 men with low- to intermediate-risk PC and found 60% of treated lesions cancer free at 6-month biopsy while preserving quality of life [83]. In the subsequent prospective phase II trial including 44 men with significant Gleason grade 2 and 3 PC, 93% were free of clinically significant PC at 5-month biopsy while 7% showed persistent disease in the treatment area [84]. Concordant with previous studies, urinary and sexual function showed an insignificant decline following HIFU but resolved at 5-month follow-up. Interestingly, no functional changes were reported for treatment volumes where the neurovascular bundle, urethra, or both were included or spared. These results are encouraging and studies showing long-term data are awaited.

Transurethral ultrasound ablation

Transurethral Ultrasound Ablation (TULSA) is performed in-bore where the HIFU probe is placed through the urethra. The reported advantage over transrectal HIFU is that it is faster and allows for a more accurate coagulation of the index tumor [85]. In feasibility studies, TULSA was well tolerated by all patients and safe to treat the whole prostate gland with a reduction of viable prostate volume by 88% 12 months after TULSA [86, 87]. A prospective multicenter trial, including 115 men with localized, low- to intermediate-risk PC, reported an average ablation delivery time of 50 min for whole gland TULSA with 98% thermal coverage of the target volume [88]. At 12-month follow-up, treatment failure for any disease was seen in 35%, and for clinically significant disease in 21%. These rates are comparable to biopsy results after external beam radiation therapy including stereotactic body radiation [89]. Functional outcome was comparable to HIFU with preservation of potency in 75% and only transient urinary dysfunction. There is still paucity in data, especially for long-term outcome.

Focal laser ablation

FLA delivers thermal laser energy through optical fibers that are placed either transrectally or transperineally under in-bore MRI- and thermometry-guidance. Data from a phase I study including 9 low-grade PC patients were promising with 78% showing no evidence of PC while 22% were downstaged to indolent disease [90]. The subsequent phase II study included 27 men with low- to intermediate-risk PC and showed a local recurrence rate of 11% after 1 year [91]. A study involving 8 men with intermediate-risk PC had a recurrence rate in the treated zone of 25% at 6-month follow-up [92]. All these studies reported no deterioration of functional outcome and good tolerance. The largest trial hitherto included 120 patients with low- to intermediate-risk PC; 17% of patients required retreatment at 1-year follow-up. No deterioration in urinary or sexual functional outcome were seen [93]. In a 3-year follow-up after FLA including 15 patients, 47% showed local recurrence whereas salvage treatment in form of repeat FLA and radical prostatectomy were performed in 27% [94]. A recently published study reported 5-year outcomes after FLA in 30 patients of which 83% remained free from failure, defined as prevention of whole gland or systemic treatment, PC metastases, or death; 40% developed in-field recurrence and required repeat ablation. [95]. Despite encouraging early results, these two studies with longer follow-up showed a decline in sexual function as well as a recurrence rate in nearly half of the cohort. One possible explanation for the high relapse rate might be related to the commonly use of a single laser fiber per treatment despite that multiple ablations may be required, potentially leading to undertreatment.

Cryotherapy

Cryotherapy induces cell apoptosis through repeat freezing and thawing of the PC lesion via transperineally or transrectally inserted cryoneedles under MRI guidance. It can be used for whole or partial gland treatment. Most studies used mpMRI-TRUS cognitive fusion for targeting the index tumor. A recent study reported 10-year oncologic outcome data of 121 men undergoing focal cryotherapy; 65% had low-, 33% intermediate-, and 2% high-risk disease [96]. Despite high overall survival (97%), half of the cohort required subsequent radical therapy. Therefore, compared to active surveillance, adding no significant oncological benefit. Up to 34% erectile dysfunction was reported – the highest within focal treatments – while urinary incontinence rates were comparably low with 5% [97–102].

Data on the performance and long-term oncological and functional outcome of MRI-guided focal therapies for PC are mostly single center, cohort studies and

often retrospective which limits a direct comparison of the techniques. Prospective head-to-head comparison or randomized, controlled trials are needed to evaluate the benefits of each local treatment approach.


The current NCCN guidelines only recommend HIFU and cryosurgery with a category 2B evidence (based upon lower-level evidence, but NCCN consensus that the intervention is appropriate) [72]. However, cryosurgery *per definitionem* refers to performing cryotherapy using an open, surgical approach. All other local therapies are not recommended as routine primary therapy due to lack of long-term data.

PET-guided focal therapies

Using PET imaging to guide focal treatment of PC has not been explored yet. An arena where PET might have a big impact is in the treatment response assessment and generally, post-therapy monitoring. This is an area of unmet clinical need as there are no non-invasive, validated methods or consensus. PSA is an unreliable marker as it falls to a variable nadir due to continued PSA production in the residual gland. Imaging with mpMRI is impeded by post-therapeutic signal alterations such as central necrosis, scar tissue formation or focal hemorrhage which decreases specificity [103, 104]. Prostate biopsy is currently the most accurate tool to evaluate response to therapy with its associated risks.

An interim analysis of a prospective study evaluated 10 men 3 months after HIFU treatment with ^{68}Ga -PSMA11 PET/MRI [105]. Recurrent disease was seen in 60% which was missed by mpMRI. Our group evaluated the feasibility of a combined approach of ^{68}Ga -PSMA11 and ^{68}Ga -RM2 PET/MRI for HIFU guidance and treatment success evaluation (NCT03949517). The preliminary results show that both ^{68}Ga -PSMA11 and ^{68}Ga -RM2 PET/MRI identified target tumors in 100% and 86%, respectively, and accurately verified response to treatment (Fig. 3). This suggests that molecular imaging might be an useful and noninvasive tool for guidance of HIFU and treatment response assessment. In patients requiring repeat focal treatment, it could be used to assist treatment planning and bypass limitations of post-treatment alterations on mpMRI.

Theranostic involves molecular-targeted imaging and treatment, and is the epitome of targeted, personalized medicine. A focal theranostic approach for localized PC has been explored preclinically based on photodynamic therapy. Photodynamic therapy is vascular-based and consists of two parts: one is the intravenous injection of a photosensitizer, which is pharmacologically inactive until exposed to the second part, which is its activation by light through transperineally inserted probes under TRUS-guidance. The activated photosensitizer transfers energy



to oxygen leading to the generation of superoxide and hydroxyl free radicals, subsequently resulting in vascular thrombosis and coagulative necrosis [106]. As a vascular photosensitizer is cleared rapidly in the blood stream, it requires multiple cycles of treatment, and uptake by surrounding healthy tissue has been a challenge. Consequently, research focused on the development of tissue-targeted photosensitizers, in particular, a conjugate of a PSMA inhibitor and photosensitizer which, after light activation, led to the desired apoptosis in tumor cells in vitro [107–109]. First in vivo studies in mice showed uptake in PSMA expressing tumor cells following systemic injection of the conjugate, and tumor growth inhibition within 1 week after exposure to light [110], and a decrease in tumor size after 2 days [111]. This concept has not been evaluated clinically but the promising pre-clinical results warrant further research in the arena of focal theragnostics for localized PC.

The VISION trial has shown impressive results in men with metastatic castration-resistant PC undergoing systematic treatment with lutetium-177 (¹⁷⁷Lu)-PSMA617

with significantly longer radiographic progression free survival (PFS) compared to standard of care treatment alone [112]. The efficacy of ¹⁷⁷Lu-PSMA617 in men with localized or locoregional advanced PC is now evaluated in the LuTectomy trial (NCT04430192). One or two cycles of ¹⁷⁷Lu-PSMA617 is given prior to prostatectomy and lymph node dissection to assess tumor absorbed doses in the prostate and any lymph node metastases. The results of this clinical trial might change the place of targeted radionuclide therapy in the treatment sequence of advanced PC.

Conclusion

Imaging with mpMRI and subsequent mpMRI-targeted biopsy have significantly improved detection of aggressive PC. Real-time in-bore image guided biopsy showed best yield in clinically significant cancers, however, also require the most resources. Given the wider availability, practicability and lower costs, MR-TRUS fusion-targeted biopsy has become the most commonly used technique.

PET/CT- or PET/MRI-targeted biopsy adds value to cases with prior negative mpMRI and/or biopsy.

In localized, nonmetastatic PC, focal therapy of the index tumor has become popular. These include transrectal, transperineal or transurethral HIFU, FLA, and cryotherapy. In-bore targeted focal therapy leverages MR thermometry with real-time heat-modulation and better treatment control. Compared to traditional whole gland treatment, significantly lower functional side effects were observed with this minimal invasive approach. All show early tumor control with each modality having different advantages and disadvantages, may it be quality of image guidance, degree of tissue destruction, or extent of ablation margin. The high local relapse rate may reflect these limitations. Subsequent repeat focal therapy or salvage whole gland treatment are feasible. Thus, initial local approaches might prolong the time to radical whole gland treatment. Prospective long-term oncologic and functional outcome data are still scarce, especially no randomized controlled trials comparing the various focal treatments to each other are yet available. However, the current data are encouraging and further studies are warranted.

Assessment of treatment response is an area of unmet clinical need. PSA decreases after treatment to a variable nadir after focal therapies, and mpMRI is limited by post-treatment artifacts that can mask in-field recurrence. Currently, post-treatment biopsy is the most accurate method for treatment verification. PET might be a suitable non-invasive modality to show treatment success. More prospective studies are needed to support the encouraging preliminary results.

Future developments include artificial intelligence and radiomics assisted risk prediction and treatment planning [113]. The use of robotic arms to support navigation and carrying out biopsy or local treatment may increase precision. Furthermore, advancement in scanner hardware and software will allow for faster MRI sequences and increased image quality. Last and most importantly, with more prospective intermediate- and long-term data, consensus guidelines for focal treatments are needed. These should address the most burning questions of whom to treat with which modality in this growing field.

Abbreviations

bpMRI: Biparametric MRI; CT: Computed Tomography; DCE: Dynamic Contrast Enhanced; DWI: Diffusion Weighted Images; ¹⁸F: Fluorine-18; FLA: Focal Laser Ablation; ⁶⁸Ga: Gallium-68; GRPR: Gastrin Releasing Peptide Receptor; HIFU: High Intensity Focused Ultrasound; ¹⁷⁷Lu: Lutetium-177; mpMRI: Multiparametric Magnetic Resonance Imaging; MRI: Magnetic Resonance Imaging; NCCN: National Comprehensive Cancer Network; PC: Prostate Cancer; PET: Positron Emission Tomography; PFS: Progression Free Survival; PI-RADS: Prostate Imaging Reporting and Data System; PSA: Prostate Specific Antigen; PSMA: Prostate Specific Membrane Antigen; T2WI: T2 Weighted Imaging; TRUS: Transrectal Ultrasound; TULSA: Transurethral Ultrasound Ablation.

Acknowledgements

Not applicable.

Authors' contributions

HD: substantial contributions to the conception and design of the work; major contributor in writing, editing, and revising the manuscript. IA: substantial contributions to the conception and design of the work; major contributor in writing, editing, and revising the manuscript. Both authors read and approved the final manuscript that has been submitted, and have agreed both to be personally accountable for the authors' own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

HD and AI declare that they have no competing interests.

Received: 17 May 2022 Accepted: 5 August 2022

Published online: 03 September 2022

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72(1):7–33.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
3. Klotz L. Active surveillance in intermediate-risk prostate cancer. *BJU Int.* 2020;125(3):346–54.
4. Pastor-Navarro B, Rubio-Briones J, Borque-Fernando A, Esteban LM, Dominguez-Escrig JL, Lopez-Guerrero JA. Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice. *Int J Mol Sci.* 2021;22(12):6266.
5. Mohler JL, Antonarakis ES. NCCN Guidelines Updates: Management of Prostate Cancer. *J Natl Compr Canc Netw.* 2019;17(5.5):583–6.
6. Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. *Lancet.* 2021;398(10305):1075–90.
7. Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. *Annu Rev Med.* 2019;70:479–99.
8. Hashine K, Kakuda T, Iuchi S, Tomida R, Matsumura M. Patient-reported outcomes after open radical prostatectomy, laparoscopic radical prostatectomy and permanent prostate brachytherapy. *Jpn J Clin Oncol.* 2019;49(11):1037–42.
9. Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2017;67(3):245–53.
10. Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzari M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ. The role of focal therapy in the management of localised prostate cancer: a systematic review. *Eur Urol.* 2014;66(4):732–51.
11. Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitterker MO, Leroy X, Mege-Lechevallier F, Comperat E, et al. Prostate cancer

- diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy—prospective multicenter study. *Radiology*. 2013;268(2):461–9.
12. Le JD, Tan N, Shkolnyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. *Eur Urol*. 2015;67(3):569–76.
 13. van der Leest M, Cornel E, Israel B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. *Eur Urol*. 2019;75(4):570–8.
 14. Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F, Decaussin-Petrucci M, Dubreuil-Chambardel M, Magaud L, Remontet L, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. *Lancet Oncol*. 2019;20(1):100–9.
 15. Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology. *J Urol*. 2017;198(2):316–21.
 16. Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgirani AM, Hsu W, Maehara CK, Ahuja P, Faiena I, Pooli A, et al. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. *Eur Urol*. 2019;75(5):712–20.
 17. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. *Cancer Res*. 1994;54(7):1807–11.
 18. Korner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. *Prostate*. 2014;74(2):217–24.
 19. Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Muntener M, Kristiansen G. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. *Prostate*. 2012;72(3):318–25.
 20. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. *Cancer Res*. 1999;59(5):1152–9.
 21. Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist—from mice to men. *Theranostics*. 2014;4(4):412–9.
 22. Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? *Lancet Oncol*. 2012;13(11):e509–17.
 23. Ahmed HU. The index lesion and the origin of prostate cancer. *N Engl J Med*. 2009;361(17):1704–6.
 24. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*. 2017;71(4):618–29.
 25. Halpern JA, Sedrakyan A, Dinerman B, Hsu WC, Mao J, Hu JC. Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis. *J Urol*. 2017;197(4):1020–5.
 26. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. *J Urol*. 2010;183(3):963–8.
 27. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *Eur Urol*. 2016;69(1):16–40.
 28. Barrett T, Rajesh A, Rosenkrantz AB, Choyke PL, Turkbey B. PI-RADS version 2.1: one small step for prostate MRI. *Clin Radiol*. 2019;74(11):841–52.
 29. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. *Eur Urol*. 2017;72(2):177–88.
 30. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet*. 2017;389(10071):815–22.
 31. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med*. 2018;378(19):1767–77.
 32. Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehravivand S, Gomella PT, Bloom J, Gurrum S, Siddiqui M, Pinsky P, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. *N Engl J Med*. 2020;382(10):917–28.
 33. Goel S, Shoag JE, Gross MD, Al Hussein Al Awamh B, Robinson B, Khani F, Baltich Nelson B, Margolis DJ, Hu JC. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2020;3(1):10–20.
 34. Klotz L, Chin J, Black PC, Finelli A, Anidjar M, Bladou F, Mercado A, Leventhal M, Ghai S, Chang SD, et al. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naïve Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2021;7(4):534–42.
 35. Pokorny M, Kua B, Esler R, Yaxley J, Samarantunga H, Dunglison N, Gianduzzo T, Coughlin G, Holt R, Laing B, et al. MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature. *World J Urol*. 2019;37(7):1263–79.
 36. Costa DN, Goldberg K, Leon AD, Lotan Y, Xi Y, Aziz M, Freifeld Y, Margulis V, Raj G, Roehrborn CG, et al. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. *Eur Urol Oncol*. 2019;2(4):397–404.
 37. Vural M, Coskun B, Kilic M, Durmaz S, Gumus T, Cengiz D, Onay A, Saglican Y, Colakoglu B, Akpek S, et al. In-bore MRI-guided prostate biopsy in a patient group with PI-RADS 4 and 5 targets: A single center experience. *Eur J Radiol*. 2021;141: 109785.
 38. Prince M, Foster BR, Kaempf A, Liu JJ, Amling CL, Isharwal S, Chen Y, Coakley FV. In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting. *AJR Am J Roentgenol*. 2021;217(5):1123–30.
 39. Schoots IG, Barentsz JO, Bittencourt LK, Haider MA, Macura KJ, Margolis DJ, Moore CM, Oto A, Panebianco V, Siddiqui MM, et al. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naïve Men With Suspected Prostate Cancer: Narrative Review. *AJR Am J Roentgenol*. 2021;216(1):3–19.
 40. Wang G, Yu G, Chen J, Yang G, Xu H, Chen Z, Wang G, Bai Z. Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men? *Clin Imaging*. 2021;88:80–6.
 41. Palumbo P, Manetta R, Izzo A, Bruno F, Arrigoni F, De Filippo M, Splendiani A, Di Cesare E, Masciocchi C, Barile A. Biparametric (bp) and multiparametric (mp) magnetic resonance imaging (MRI) approach to prostate cancer disease: a narrative review of current debate on dynamic contrast enhancement. *Gland Surg*. 2020;9(6):2235–47.
 42. Wallstrom J, Geterud K, Kohistani K, Maier SE, Mansson M, Pihl CG, Socratous A, Arnsrud Godtman R, Hellstrom M, Hugosson J. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial. *Eur Radiol*. 2021;31(11):8692–702.
 43. Russo F, Mazzetti S, Regge D, Ambrosini I, Giannini V, Manfredi M, De Luca S, Bollito E, Porpiglia F. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men. *Eur Urol Oncol*. 2021;4(6):855–62.
 44. Prostate Cancer Early Detection (Version 1.2022) [https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf]
 45. Sparwasser P, Haack M, Epple S, Frey L, Zeymer S, Dotzauer R, Jungmann F, Bohm K, Hofner T, Tsaur I, et al. Smartglass augmented reality-assisted targeted prostate biopsy using cognitive point-of-care fusion technology. *Int J Med Robot*. 2022;18(3):e2366.

46. Helfrich O, Puech P, Betrouni N, Pincon C, Ouzzane A, Rizk J, Marcq G, Randazzo M, Durand M, Lakroum S, et al. Quantified analysis of histological components and architectural patterns of gleason grades in apparent diffusion coefficient restricted areas upon diffusion weighted MRI for peripheral or transition zone cancer locations. *J Magn Reson Imaging*. 2017;46(6):1786–96.
47. Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, Huang J, Grundfest W, Marks LS. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. *J Urol*. 2017;197(2):320–6.
48. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. *Nat Rev Urol*. 2016;13(4):226–35.
49. Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, et al. Detection and localisation of primary prostate cancer using (68) gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. *BJU Int*. 2020;126(1):83–90.
50. Berger I, Annabattula C, Lewis J, Shetty DV, Kam J, Maclean F, Ariyanagam M, Canagasingham B, Ferguson R, Khadra M, et al. (68) Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. *Prostate Cancer Prostatic Dis*. 2018;21(2):204–11.
51. Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA. Diagnostic Accuracy of (68)Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. *Radiology*. 2018;289(3):730–7.
52. Liu C, Liu T, Zhang Z, Zhang N, Du P, Yang Y, Liu Y, Yu W, Li N, Gorin MA, et al. (68)Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results. *J Nucl Med*. 2020;61(9):1314–9.
53. Ferraro DA, Becker AS, Kranzbuhler B, Mebert I, Baltensperger A, Zeimpekis KG, Grunig H, Messerli M, Rupp NJ, Rueschoff JH, et al. Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. *Eur J Nucl Med Mol Imaging*. 2021;48(10):3315–24.
54. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. *Prostate*. 2011;71(3):281–8.
55. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kubler H, Beer AJ, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. *J Urol*. 2016;195(5):1436–43.
56. Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, Rasiah K, Pattison DA, Yaxley J, Thomas P, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. *Eur Urol*. 2021;80(6):682–9.
57. Zhang LL, Li WC, Xu Z, Jiang N, Zang SM, Xu LW, Huang WB, Wang F, Sun HB. (68)Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. *Eur J Nucl Med Mol Imaging*. 2021;48(2):483–92.
58. Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, Boellaard R, Hendrikse NH, Hoekstra OS, van Moorselaar RJA, et al. Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial *World J Urol*. 2021;39(7):2439–46.
59. Liu Y, Yu H, Liu J, Zhang X, Lin M, Schmidt H, Gao J, Xu B. A Pilot Study of (18)F-DCFPyL PET/CT or PET/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions. *Front Oncol*. 2021;11:612157.
60. Sasikumar A, Joy A, Nanabala R, Pillai MR. T AH: 68Ga-PSMA PET/CT False-Positive Tracer Uptake in Paget Disease. *Clin Nucl Med*. 2016;41(10):e454-455.
61. Noto B, Vrachimis A, Schafers M, Stegger L, Rahbar K. Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT. *Clin Nucl Med*. 2016;41(10):e449-451.
62. Hermann RM, Djannatian M, Czech N, Nitsche M. Prostate-Specific Membrane Antigen PET/CT: False-Positive Results due to Sarcoidosis? *Case Rep Oncol*. 2016;9(2):457–63.
63. Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. *Ann Nucl Med*. 2015;29(10):877–82.
64. Verburg FA, Krohn T, Heinzl A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [(6)(8)Ga]PSMA-HBED-CC PET/CT. *Eur J Nucl Med Mol Imaging*. 2015;42(10):1622–3.
65. Schwenck J, Tabatabai G, Skardelly M, Reischl G, Beschoner R, Pichler B, la Fougere C. In vivo visualization of prostate-specific membrane antigen in glioblastoma. *Eur J Nucl Med Mol Imaging*. 2015;42(1):170–1.
66. Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzl A, Mottaghy FM, Behrendt FF. [(6)(8)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. *Eur J Nucl Med Mol Imaging*. 2015;42(2):210–4.
67. Qiu DX, Li J, Zhang JW, Chen MF, Gao XM, Tang YX, Zhang Y, Yi XP, Yin HL, Gan Y, et al. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. *Eur J Nucl Med Mol Imaging*. 2022;49(8):2821–32.
68. Duan H, Ferri V, Ghanouni P, Daniel B, Hatami N, Davidson G, Aparici C, Moradi F, Thong A, Sonn G, et al. A Pilot Study of 68Ga-PSMA11 PET/MRI and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. *J Nucl Med*. 2021;62:1348.
69. Minamimoto R, Sonni I, Hancock S, Vasanawala S, Loening A, Gambhir SS, Iagaru A. Prospective Evaluation of (68)Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging. *J Nucl Med*. 2018;59(5):803–8.
70. Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, et al. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. *Eur Urol Oncol*. 2019;2(2):166–73.
71. Kumar R, Singh SK, Mittal BR, Vadi SK, Kakkar N, Singh H, Krishnaraju VS, Kumar S, Bhattacharya A. Safety and Diagnostic Yield of (68)Ga Prostate-specific Membrane Antigen PET/CT Guided Robotic-assisted Transgluteal Prostatic Biopsy. *Radiology*. 2022;303(2):392–8.
72. National Comprehensive Cancer Network. Prostate Cancer (Version 4.2022). 2022.
73. Lovegrove CE, Peters M, Guillaumier S, Arya M, Afzal N, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, et al. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. *BJU Int*. 2020;125(6):853–60.
74. Shah TT, Reddy D, Peters M, Ball D, Kim NH, Gomez EG, Miah S, Evans DE, Guillaumier S, van Rossum PSN, et al. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. *Prostate Cancer Prostatic Dis*. 2021;24(2):567–74.
75. Le Nobin J, Orczyk C, Deng FM, Melamed J, Rusinek H, Taneja SS, Rosenkrantz AB. Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software. *BJU Int*. 2014;114(6b):E105–12.
76. Le Nobin J, Rosenkrantz AB, Villers A, Orczyk C, Deng FM, Melamed J, Mikheev A, Rusinek H, Taneja SS. Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis. *J Urol*. 2015;194(2):364–70.
77. Pooli A, Johnson DC, Shirk J, Markovic D, Sadun TY, Sisk AE Jr, Mohamadian Bajgiran A, Afshari Mirak S, Felker ER, Hughes AK, et al. Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. *J Urol*. 2021;205(2):444–51.

78. Lindner U, Trachtenberg J, Lawrentschuk N. Focal therapy in prostate cancer: modalities, findings and future considerations. *Nat Rev Urol*. 2010;7(10):562–71.
79. Marien A, Gill I, Ukimura O, Betrouni N, Villers A. Target ablation–image-guided therapy in prostate cancer. *Urol Oncol*. 2014;32(6):912–23.
80. Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. *Eur Urol*. 2018;74(4):422–9.
81. Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C, et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. *BJU Int*. 2019;124(3):431–40.
82. Tay KJ, Cheng CWS, Lau WKO, Khoo J, Thng CH, Kwek JW. Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial–Complications and Functional Outcomes. *Radiology*. 2017;285(2):620–8.
83. Ghai S, Perlis N, Lindner U, Hlasny E, Haider MA, Finelli A, Zlotta AR, Kulkarni GS, van der Kwast TH, McCluskey SA, et al. Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. *Eur Radiol*. 2018;28(10):4281–7.
84. Ghai S, Finelli A, Corr K, Chan R, Jokhu S, Li X, McCluskey S, Konukhova A, Hlasny E, van der Kwast TH, et al. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. *Radiology*. 2021;299(2):E258.
85. Burtnyk M, Chopra R, Bronskill MJ. Quantitative analysis of 3-D conformal MRI-guided transurethral ultrasound therapy of the prostate: theoretical simulations. *Int J Hyperthermia*. 2009;25(2):116–31.
86. Chin JL, Billia M, Relle J, Roethke MC, Popenciu IV, Kuru TH, Hatiboglu G, Mueller-Wolf MB, Motsch J, Romagnoli C, et al. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. *Eur Urol*. 2016;70(3):447–55.
87. Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, Kuru TH, Popenciu IV, Chin JL, Billia M, et al. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. *Eur Radiol*. 2019;29(1):299–308.
88. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Futterer J, Serrallach M, et al. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. *J Urol*. 2021;205(3):769–79.
89. Singh S, Moore CM, Punwani S, Mitra AV, Bandula S. Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2021;24(3):612–22.
90. Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. *Radiology*. 2013;267(3):932–40.
91. Eggener SE, Yousuf A, Watson S, Wang S, Oto A. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. *J Urol*. 2016;196(6):1670–5.
92. Natarajan S, Raman S, Priester AM, Garritano J, Margolis DJ, Lieu P, Macairan ML, Huang J, Grundfest W, Marks LS. Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. *J Urol*. 2016;196(1):68–75.
93. Walsler E, Nance A, Ynalvez L, Yong S, Aoughsten JS, Eyzaguirre EJ, Williams SB. Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low-to Intermediate-Risk Disease. *J Vasc Interv Radiol*. 2019;30(3):401–9 e402.
94. Mehralivand S, George AK, Hoang AN, Rais-Bahrami S, Rastinehad AR, Lebastchi AH, Ahdoot M, Siddiqui MM, Bloom J, Sidana A, et al. MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up. *Diagn Interv Radiol*. 2021;27(3):394–400.
95. Chao B, Lepor H. 5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer. *Urology*. 2021;155:124–9.
96. Marra G, Soeterik T, Oreggia D, Tourinho-Barbosa R, Moschini M, Filippini C, et al. Long-term outcomes of focal cryotherapy for low- to intermediate-risk prostate cancer: results and matched pair analysis with active surveillance. *Eur Urol Focus*. 2021. <https://doi.org/10.1016/j.euf.2021.04.008>.
97. Valerio M, Shah TT, Shah P, McCartan N, Emberton M, Arya M, Ahmed HU. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study. *Urol Oncol*. 2017;35(4):150 e151–150 e157.
98. Woodrum DA, Kawashima A, Karnes RJ, Davis BJ, Frank I, Engen DE, Gorny KR, Felmler JP, Callstrom MR, Mynderse LA. Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience. *Urology*. 2013;82(4):870–5.
99. Mendez MH, Passoni NM, Pow-Sang J, Jones JS, Polascik TJ. Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. *J Endourol*. 2015;29(10):1193–8.
100. Sze C, Tsivian E, Tay KJ, Schulman AA, Davis LG, Gupta RT, Polascik TJ. Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multiparametric magnetic resonance imaging. *BMC Urol*. 2019;19(1):127.
101. Oishi M, Gill IS, Tafuri A, Shakir A, Cacciamani GE, Iwata T, Iwata A, Ashrafi A, Park D, Cai J, et al. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years. *J Urol*. 2019;202(6):1188–98.
102. Tan WP, Chang A, Sze C, Polascik TJ. Oncologic and Functional Outcomes of Patients Undergoing Individualized Partial Gland Cryoablation of the Prostate: A Single-Institution Experience. *J Endourol*. 2021;35(9):1290–9.
103. Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, Dubernard JM, Gelet A. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. *Eur Urol*. 2001;40(3):265–74.
104. Rosenkrantz AB, Taneja SS. Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. *AJR Am J Roentgenol*. 2014;202(1):109–20.
105. Burger IA, Muller J, Donati OF, Ferraro DA, Messerli M, Kranzbuehler B, TerVoert E, Muehlematter UJ, Rupp NJ, Mortezaei A, et al. (68)Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. *J Nucl Med*. 2019;60(8):1118–23.
106. Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsone E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol*. 2017;18(2):181–91.
107. Liu T, Wu LY, Choi JK, Berkman CE. In vitro targeted photodynamic therapy with a pyropheophorbide–a conjugated inhibitor of prostate-specific membrane antigen. *Prostate*. 2009;69(6):585–94.
108. Liu T, Wu LY, Berkman CE. Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. *Cancer Lett*. 2010;296(1):106–12.
109. Liu T, Wu LY, Choi JK, Berkman CE. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. *Int J Oncol*. 2010;36(4):777–84.
110. Wang X, Tsui B, Ramamurthy G, Zhang P, Meyers J, Kenney ME, Kiechle J, Ponsky L, Basilion JP. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen. *Mol Cancer Ther*. 2016;15(8):1834–44.
111. Chen Y, Chatterjee S, Lisok A, Minn I, Pullambhatla M, Wharram B, Wang Y, Jin J, Bhujwala ZM, Nimmagadda S, et al. A PSMA-targeted theranostic agent for photodynamic therapy. *J Photochem Photobiol B*. 2017;167:111–6.
112. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2021;385(12):1091–103.
113. Hectors SJ, Cherny M, Yadav KK, Beksac AT, Thulasidass H, Lewis S, Davicioni E, Wang P, Tewari AK, Taouli B. Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness. *J Urol*. 2019;202(3):498–505.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.